Investors

• Investor Information
• Press Releases
• Events & Presentations
• Corporate Governance
• Financial Information
• SEC Filings
• Stock Information
• Investor FAQs
• Contact Us

Print page     Email page

Board of Directors

show all hide all

Martin Sutter - Lead Director

Martin Sutter has served as a member of our board of directors since April 2004 and was appointed Lead Director in August 2007. Since 1988, Mr. Sutter has served as Managing Director of Essex Woodlands Health Ventures, a venture capital partnership focused on healthcare investments and previously served as a Managing Director of one of its predecessors. Mr. Sutter serves as a member of the board of directors of LifeCell, a publicly-traded biotechnology company, and La Jolla Pharmaceutical, a publiclytraded biopharmaceutical company. He currently serves on the board of directors of several privatelyheld life science companies. Mr. Sutter holds a B.S. from Louisiana State University and an M.B.A. from the University of Houston.

Member of the Audit Committee
Member of the Nominating and Governance Committee

Steve Basta - Chief Executive Office and Director

Steve Basta has been our Chief Executive Officer since November 2002, also serving as President from November 2002 to June 2007. From December 2000 to November 2002, he was President, and later Chief Executive Officer, of Gliatech, a publicly-traded medical device and drug discovery company. Prior to joining Gliatech, Mr. Basta was Vice President, Business Development of Creative BioMolecules from 1997 to 2000, and served as its Chief Financial Officer from 1999 to 2000. Mr. Basta holds a B.A. from The Johns Hopkins University and a Masters in Management from the Kellogg Graduate School of Management at Northwestern University.

Albert Cha M.D., Ph.D. - Director

Albert Cha, M.D., Ph.D. has served as a member of our board of directors since June 2002. In 2000, Dr. Cha joined Vivo Ventures, a life science venture capital firm, where he has served in various positions, most recently as a Managing Partner. Dr. Cha currently serves on the board of directors of BioDel, a publicly-traded development stage pharmaceutical company. He currently serves as a member of the board of directors of several privately-held biotechnology and medical device companies. Dr. Cha holds a B.S. and an M.S. from Stanford University and an M.D. and a Ph.D. from the University of California at Los Angeles.

Member of the Nominating and Governance Committee
Member of the Compensation Committee

N.C. Joseph Lai Ph.D. - Director

N.C. Joseph Lai, Ph.D. is our founder and has been a member of our board of directors since July 1999. From July 1999 to November 2002, Dr. Lai served as our President and Chief Executive Officer. From November 2002 to November 2005, Dr. Lai served as our Executive Chairman. From November 2005 to August 2007, he served as Chairman of our board of directors. Dr. Lai was a co-founder of Criticare Systems, a publicly-traded medical device company, and served as an officer from the company's inception in October 1984 until November 1998. Dr. Lai currently serves as a member of the board of directors of Criticare Systems. Dr. Lai holds a B.S. from Cornell University, an M.S. from Northeastern University and Ph.D. from the University of Pittsburgh.

Tim Lynch - Director

Tim Lynch has served as a member of our board of directors since July 2006. Since October 2005, Mr. Lynch has served as President and Chief Executive Officer of NeuroStat Pharmaceuticals, a specialty pharmaceutical company. From June 2005 through September 2005, Mr. Lynch was President and Chief Executive Officer of Vivo Therapeutics, a specialty pharmaceuticals company. From October 2002 through June 2005, Mr. Lynch served as Chief Financial Officer of Tercica, a publicly-traded biopharmaceutical company. From 1999 to June 2002, Mr. Lynch served as Chief Financial Officer of InterMune, a publicly-traded biopharmaceutical company. Currently, Mr. Lynch serves as a member of the board of directors of both Nabi Biopharmaceuticals, a publicly-traded biopharmaceutical company, and Allos Therapeutics, a publicly-traded biotechnology company. Mr. Lynch holds a B.A. from Colgate University and an M.B.A. from the Harvard Graduate School of Business.

Member of the Audit Committee

Evan Melrose M.D. - Director

Evan Melrose, M.D., has served as a member of our board of directors since June 2003. Since January 2003, Dr. Melrose has been a Managing Director of PTV Sciences, L.P., a venture capital firm. From 2001 to January 2003, Dr. Melrose was a director with Burrill & Company, a life science venture capital firm. Dr. Melrose currently serves as a member of the board of directors of several privately-held life science companies. Dr. Melrose holds a B.A. degree from the University of Pennsylvania, an M.D. from Indiana University and an M.B.A. from the Wharton School of the University of Pennsylvania.

Member of the Audit Committee
Member of the Compensation Committee

Kevin Sidow - Director

Kevin Sidow has served as a member of our board of directors since July 2007. Mr. Sidow served as President and Chief Executive Officer and as a member of the board of directors of St. Francis Medical Technologies from May 2004 until the company was acquired by Kyphon, a publicly-traded orthopedic company, in January 2007. From 1998 to May 2004, Mr. Sidow held a number of executive positions with DePuy, a subsidiary of Johnson & Johnson and a designer, manufacturer and distributor of medical devices. From October 2003 to May 2004, he was Worldwide President of DePuy, and from March 2001 to October 2003, he served as Worldwide President of DePuy Orthopaedics, ACE and Casting. Mr. Sidow holds a B.S. from West Virginia University.

Member of the Nominating and Governance Committee
Member of the Compensation Committee

back to top